AZN.L - AstraZeneca PLC
| Previous close | 7,230.00 |
| Open | 7,286.00 |
| Bid | 6,200.00 x 0 |
| Ask | 7,500.00 x 0 |
| Day's range | 7,219.00 - 7,315.00 |
| 52-week range | 5,312.00 - 7,475.15 |
| Volume | 1,389,045 |
| Avg. volume | 2,110,043 |
| Market cap | 95.19B |
| Beta (3Y monthly) | 1.05 |
| PE ratio (TTM) | 42.38 |
| EPS (TTM) | 171.20 |
| Earnings date | 24 Oct 2019 |
| Forward dividend & yield | 2.19 (3.02%) |
| Ex-dividend date | 2019-08-08 |
| 1y target est | 78.83 |
- Motley Fool
3 Healthcare Stocks at All-Time Highs: Are They Buys?
They're flying high right now. But are these three healthcare stocks smart picks?
- Business Wire
CALQUENCE® (acalabrutinib) Granted US Breakthrough Therapy Designation for Chronic Lymphocytic Leukemia
Designation based on positive results from two Phase III trials
- Business Wire
LYNPARZA® (olaparib) Phase III Paola-1 Trial Met Primary Endpoint as 1st-line Maintenance Treatment With Bevacizumab for Advanced Ovarian Cancer
AstraZeneca and Merck’s LYNPARZA when added to standard-of-care bevacizumab significantly increased the time women lived without disease progression or death
- Reuters - UK Focus
AstraZeneca scores win in race to treat ovarian cancer
AstraZeneca has made further headway in the race with larger competitor GlaxoSmithKline's to use a promising new class of drugs to treat ovarian cancer. Astra said on Wednesday its Lynparza drug, which blocks a cancer's ability to repair its genetic code during cell division, was shown to slow the progression of ovarian cancer that has started to spread in the body. The patient group that was examined in the so-called Paola-1 trial had been successfully given chemotherapy and Roche's Avastin as initial treatment following a diagnosis of advanced ovarian cancer.
- Reuters - UK Focus
No-deal Brexit could deepen Europe's shortage of medicines - experts
As the Oct. 31 deadline for Britain to leave the European Union approaches, health professionals are warning that shortages of some medicines could worsen in Europe in the event of a no-deal Brexit. Britain's food and drink lobby warned last week that the country would experience shortages of some fresh foods if there is a disorderly no-deal Brexit.
- Fool.co.uk
Have £5k to spend? 2 FTSE 100 dividend stocks I’d buy for 2020 and beyond
Looking for great FTSE 100 (INDEXFTSE: UKX) income heroes to buy for 2020? These two could be just the ticket, argues Royston Wild.
- Business Wire
TAGRISSO® (OSIMERTINIB) Significantly Improves Overall Survival in the Phase III FLAURA Trial for 1st-line EGFR-mutated Non-small Cell Lung Cancer
TAGRISSO is the only medicine demonstrating statistically-significant overall survival benefit in this setting. AstraZeneca today announced positive overall survival (OS) results from the Phase III FLAURA trial, a randomized, double-blinded, multicenter trial of TAGRISSO in previously-untreated patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) mutations.
- Reuters - UK Focus
LIVE MARKETS-Trade war "killed my performance"
- Reuters - UK Focus
MORNING BID EUROPE-On the brink: Salvini wants snap elections
Italy's government is on the brink of collapse after the leader of the ruling League party, Matteo Salvini, called the governing coalition with 5-Star unworkable and said the only way forward was to hold fresh elections. 5-Star has more parliamentary seats than the League, but Salvini's party now has twice as much voter support, polls show, making it well placed to benefit from a snap election.
- Reuters - UK Focus
LIVE MARKETS-Opening snapshot: It's all about Italy
- Reuters - UK Focus
LIVE MARKETS-Europe heading for weak open; Italy, chipmakers in focus
- Business Wire
LYNPARZA® (Olaparib) Phase III Profound Trial in HRR* Mutation-Selected Metastatic Castration-Resistant Prostate Cancer Met Primary Endpoint
AstraZeneca and Merck’s LYNPARZA Met the Primary Endpoint of Significantly Increasing the Time Patients Selected for BRCA1/2 or ATM Mutations Live Without Radiographic Disease Progression vs.
- Bloomberg
The CEO Who Capped a $37 Billion Recovery With a Cancer Drug Deal
(Bloomberg) -- The future looked bleak for Japanese drugmaker Daiichi Sankyo Co. when George Nakayama took over as chief executive officer in 2010.The stock was in the middle of a six-year free fall, its Indian subsidiary Ranbaxy Laboratories Ltd. was banned by the U.S. from selling products there, and a new anti-clotting medicine was slapped with the strictest safety warning.Nakayama, a former salesman for one of Japan’s biggest brewers, decided to reboot Daiichi Sankyo, pivoting away from generic medicines and toward the more lucrative business of cancer drugs. He sold scandal-ridden Ranbaxy for $3.2 billion, acquired two U.S.-based makers of cancer medicines and focused research on a class of drugs that could replace chemotherapy.Affirmation arrived in March, when British drugmaker AstraZeneca Plc agreed to pay as much as $6.9 billion to jointly develop one of those medicines, known as antibody drug conjugates, for patients of breast and other cancers. Under Nakayama’s turnaround plan, Daiichi Sankyo’s stock has rocketed 470% to an all-time high -- adding $37 billion in market value to make it Japan’s second-biggest drugmaker after Takeda Pharmaceutical Co.“So many things happened, but I was extremely lucky,” Nakayama, 69, said during a July 12 interview. “Looking back, it was a pretty tough start. It got better over time.”Soon after the deal, Nakayama ceded the CEO title to Sunao Manabe, a veterinarian by training, though Nakayama remains chairman. He’s leaving on a high note, with Daiichi Sankyo the best performer this year on an MSCI index of the biggest drugmakers. The stock climbed 0.7% to a fresh record on Tuesday, while Japan’s benchmark Topix index fell 0.4%.Analysts say the future looks bright for the Tokyo-based company, formed in 2005 through the merger of Daiichi Pharmaceutical Co. and Sankyo Co. Revenue is expected to increase 14% through 2023, while operating profit is seen surging 78%, according to analysts surveyed by Bloomberg.“The strategy shift is now starting to pay off,” said Yasuhiro Nakazawa, an analyst at SMBC Nikko Securities Inc. in Tokyo. “Daiichi Sankyo is really betting on the new direction as a whole.”That blueprint is anchored by the cancer drug known as DS-8201, which the company plans to seek U.S. approval for by Sept. 30. Daiwa Securities Co. analyst Kazuaki Hashiguchi predicts it will reach almost $8 billion in annual sales by 2030, surpassing Roche Holding AG’s breast-cancer drug Herceptin, which DS-8201 seeks to replace.The drug’s potential as a blockbuster medicine comes as global pharmaceutical giants are scrambling to transform themselves to replace aging pipelines. Cancer has become one of the hottest areas for deal activity between drug and biotechnology companies, as scientific advances are leading to new tailored therapies with strong growth potential.Daiichi Sankyo partnered with AstraZeneca to develop and commercialize DS-8201, and the two companies agreed to split profit and costs. Such ADCs are a class of drugs that can attack cancer cells in the body without damaging surrounding healthy ones. Analysts say DS-8201 could triple the number of patients who receive targeted treatment for breast cancer, which kills more than 500,000 women annually.“This Daiichi Sankyo drug has the potential to transform cancer care, so it is a very important product for us and, of course, for our partner,” Pascal Soriot, CEO of AstraZeneca, said in a July 25 interview on Bloomberg Television.Daiichi Sankyo is developing about a dozen cancer-fighting compounds, and considering further partnerships. It will devote a “significant portion” of its research budget toward successfully bringing them to the market, Manabe said in a July 9 interview. “Compared with a few years ago, our cancer pipeline is very rich now,” Manabe said.This new focus represents a sea change for Daiichi Sankyo, which was saddled with headaches when Nakayama took over. His early priority was to save Ranbaxy’s operations. Two of the Indian company’s four plants faced U.S. bans because of data fabrication, so Nakayama tried to strengthen the remaining two. His efforts fizzled, and they were banned by the U.S. starting in 2013.“We just couldn’t quite grasp the depth of Ranbaxy’s data falsification,” Nakayama said.Daiichi Sankyo found a buyer in Indian rival Sun Pharmaceutical Industries Ltd. in 2014. But its problems weren’t over. Daiichi Sankyo paid a $39 million fine in 2015 to settle U.S. allegations it gave kickbacks to doctors in exchange for prescribing company medicines. Most of the alleged infractions occurred before Nakayama’s tenure. That same year, its blood thinner edoxaban received U.S. approval but carried a “boxed warning” about use by certain patients, limiting its market potential.Shifting FocusNakayama decided the company needed a change, so he sold the Sun Pharmaceutical stake and shifted his focus to cancer drugs, overhauling operations, making acquisitions and hiring Antoine Yver, who ran the oncology unit at AstraZeneca, in April 2016.Daiichi Sankyo previously spent more than $1 billion to gain cancer medicines through takeovers of Plexxikon Inc. in 2011 and Ambit Biosciences Corp. in 2014, and its ADCs were showing promise in early testing.“The global oncology market became subdivided and not a single winner could take it all,” Nakayama said. “If we had the world-class science and acted fast, we had a chance.”The former CEO also takes a humble view of the company’s turnaround, giving some credit to fortune: in finding a buyer for Ranbaxy, having labs produce new compounds at the right time, latching onto AstraZeneca’s Yver to run the cancer business.“God made the timing well,” Nakayama said.To contact the reporters on this story: Kanoko Matsuyama in Tokyo at kmatsuyama2@bloomberg.net;Grace Huang in Tokyo at xhuang66@bloomberg.netTo contact the editors responsible for this story: Rachel Chang at wchang98@bloomberg.net, Michael Tighe, Jeff SutherlandFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
- Fool.co.uk
Should I buy Sirius Minerals shares?
Is Sirius Minerals plc (LON:SXX) appealing, or would a 'jam today' stock (that has future potential too) beat its 'jam tomorrow' attractions for me?
- Motley Fool
3 Lung Cancer Stocks That Could Soar in September
These industry giants could make big moves after this year's World Conference on Lung Cancer.
- Simply Wall St.
It Might Be Better To Avoid AstraZeneca PLC's (LON:AZN) Upcoming 1.0% Dividend
AstraZeneca PLC (LON:AZN) is about to trade ex-dividend in the next 3 days. Ex-dividend means that investors that...
- Fool.co.uk
Top shares for August 2019
We asked our freelance writers to share their top stock picks for the month.
- Motley Fool
10 Biggest Cancer-Fighting Stocks
The fight against cancer is a big battle. And these 10 companies are among the biggest combatants you can invest in.
- Fool.co.uk
2 FTSE 100 shares I’d buy today
Manika Premsingh thinks FTSE 100 (INDEXFTSE: UKX) giants AstraZeneca plc (LON: AZN) and GlaxoSmithKline plc (LON: GSK) could see further share price increases with healthy results and uncertainty driving investors towards defensives.
- Fool.co.uk
Why I think the AstraZeneca share price will keep climbing
A portfolio of new drugs could mean it’s time to invest in AstraZeneca plc (LON: AZN).
- Motley Fool
Why AstraZeneca, Ambev, and Nokia Jumped Today
Solid earnings lifted some stocks despite a big market downturn.
- Market Realist
AstraZeneca Rises on Its Earnings Beat
AstraZeneca (AZN) reported its second-quarter earnings results on July 25. The stock is already up 6.39% on the day and is trading close to $42.91.
- Yahoo Finance
Pharma giants eye 'period of change' as drug pricing talk heats up in DC
Major pharmaceutical giants acknowledge change is on the horizon amid mounting political pressures over costly medicine.
- Reuters - UK Focus
LIVE MARKETS-Closing snapshot: Mario giveth and then he taketh away
* European stocks end sharply lower after rollercoaster day * ECB signals rate cut in September, more QE, triggering brief rally * Stock gains wiped out after ECB's Draghi quashes talk of rate cut today * EZ banks briefly rallied on tiered rate hopes, but gains evaporated * German business morale deteriorates * CAC 40 outperformed broader market on solid updates from LVMH, Schneider Electric * Nokia rose 7% after surprise Q2 profit jump * Cobham +35% after Advent agrees to buy for $5 billion Welcome to the home for real-time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Thyagaraju Adinarayan. Reach him on Messenger to share your thoughts on market moves: rm://thyagaraju.adinarayan.thomsonreuters.com@reuters.net CLOSING SNAPSHOT: MARIO GIVETH AND THEN HE TAKETH AWAY (1558 GMT) The ECB's bank's policy statement delivered much of what the market had expected, signalling a September rate cut, changes to inflation targets, more QE and a gift to banks with possible tiered deposit rates and the ensuing euphoria sent euro-zone stocks rallying, led by banks.
- Reuters - UK Focus
CORRECTED-LIVE MARKETS-No bazooka!
